Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Completed · Not applicable · Has a placebo group

Conditions studied: Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus

In brief

The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.

Key facts

Study ID

NCT00413335

Run by

Yale University

People needed

21

Starts

2005-11-01

Expected to finish

2008-12-01

Last updated by the study team

2013-07-22

Who can join

Age: 10 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Good general health
• Aged 10 to 18 yrs (females: Tanner stage II-V;and males:testes size>6ml)
• IGT based on 2-hr plasma glucose>140mg/dl and <200mg/dl during an OGTT.

You may not qualify if…

• Baseline creatinine>1.0mg
• AST and ALT>2.5 ULN
• Anemia (Hct<30)
• Pregnancy (females must have a negative urine pregnancy test during the study)
• Cardiac or pulmonary or other significant chronic illness
• Plans to increase the frequency or intensity of a regular exercise program
• Psychiatric disorder or substance abuse of anorexic agents.

Where it is running

• Yale School of Medicine — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.